Abstract
PD41-11 LONGITUDINAL FOLLOW UP OF MULTICENTER STUDY OF UGN-101 FOR UPPER TRACT UROTHELIAL CANCER
The Journal of urology, Vol.211(5S), p.e890
05/2024
DOI: 10.1097/01.JU.0001008568.76803.f1.11
Abstract
INTRODUCTION AND OBJECTIVE:
UGN-101 is a novel therapeutic for the treatment of upper tract urothelial cancer (UTUC) but there is a lack of longitudinal data on efficacy. This study evaluated a large multicenter cohort of patients treated with UGN-101, with longest follow up available in the literature.
METHODS:
Data was collected from 15 centers on patients treated with UGN-101 for UTUC. Recurrence free survival (RFS) was calculated only for patients who had no evidence of disease following UGN-101 induction. Progression free survival (PFS) was calculated for all patients treated with UGN-101. Disease progression was defined as: i) grade progression from low-grade to high-grade disease, ii) stage progression, or iii) development of metastatic disease. Receipt of maintenance was defined as dichotomously, although practice patterns varied.
RESULTS:
There were 136 cases of UTUC treated with UGN-101 with a cumulative median (IQR) follow up of 22 (12-27) months including 107 cases of LGTa UTUC. PFS was 87% at 24 months. Within the subset of 53 cases with LGTa UTUC without evidence of disease following UGN-101 induction – the median time to recurrence was not reached. RFS at 24-months was 86%. Among initial responders, 30% received maintenance therapy. RFS at 24 months was 100% and 61% for patients who received maintenance versus no maintenance, respectively (log rank 0.014). There were 9 cases of high-grade and presumed non-invasive disease treated with UGN-101 who had follow-up available. The median risk of progression was 50% at 12 months. In the subset of 4 cases with HGTa disease who had a negative initial endoscopic evaluation – half had recurred by 10 months.
CONCLUSIONS:
UGN-101 treatment appears to demonstrate favorable recurrence free survival rates in patients with LGTa UTUC. Administration of maintenance appears to be associated with significantly better RFS. Due to small numbers of patients with high-grade disease, our analysis is limited however there is significant concern for high risk of recurrence and progression in this cohort.
Details
- Title: Subtitle
- PD41-11 LONGITUDINAL FOLLOW UP OF MULTICENTER STUDY OF UGN-101 FOR UPPER TRACT UROTHELIAL CANCER
- Creators
- Solomon L. WolduBrett JohnsonKatie S. MurrayHiroko MiyagiWade SextonIsamu TachibanaHristos KaimakliotisJoseph JacobRian DicksteinJennifer LinehanAlan NiederMarc BjurlinDaniel HeidenbergMitchell HumphreysSaum GhodoussipourMarcus L. QuekMichael O'DonnellBrian EisnerSurena MatinAdam S. FeldmanYair Lotan
- Resource Type
- Abstract
- Publication Details
- The Journal of urology, Vol.211(5S), p.e890
- DOI
- 10.1097/01.JU.0001008568.76803.f1.11
- ISSN
- 0022-5347
- eISSN
- 1527-3792
- Language
- English
- Date published
- 05/2024
- Academic Unit
- Urology
- Record Identifier
- 9984649158402771
Metrics
2 Record Views